Aktuellt
SENASTE
Redeye comments on Medivir's Q4 report of 2024. In the quarter, the phase IIa study of fostrox was completed. In the conference call, new information about the planned phase IIb study, FOcuS-2, was presented. Furthermore, we present a new valuation model with a new base case.
LÄS MER
